Skip to content
PeptideAI
Approved drugfat lossblood sugar

Ecnoglutide

cAMP-biased long-acting GLP-1 analogue newly approved in China for weight management, delivering about 13% placebo-adjusted weight loss at 2.4 mg weekly.

Also known as cAMP-biased GLP-1 analogue, XW003, XW004

Approved drug — Licensed by a major regulator for human use, with phase-3 trial data behind it.

Approved by China's NMPA in January 2026 for chronic weight management on the basis of the phase 3 SLIMMER trial, with separate phase 3 data in type 2 diabetes (EECOH-2) showing non-inferiority to dulaglutide. Not evaluated by FDA or EMA.

How it works

Ecnoglutide is a GLP-1 analogue designed for biased agonism: it preferentially activates Gs-coupled cAMP production while recruiting comparatively little beta-arrestin. Because beta-arrestin drives receptor internalisation and desensitisation, the intended result is more durable receptor signalling and better insulinotropic efficiency per unit exposure. Whether the biased signalling actually explains its clinical results or whether it is simply a well-designed long-acting analogue is not settled. Clinically it behaves like a standard weekly GLP-1: appetite suppression, delayed gastric emptying, glucose-dependent insulin release. An oral tablet formulation (XW004) is also in development.

Targets: GLP-1 receptor

Dosing

ProtocolDoseFrequencyRoute
Phase 3 SLIMMER weight-management titrationSame day each week.600 mcg – 2.4 mgonce weeklysubcutaneous
  • · Escalated from 600 mcg weekly through 1200 and 1800 to a maintenance dose of 1800 or 2400 mcg. The 2.4 mg arm gave roughly 13% placebo-adjusted weight reduction at week 48, with lower doses in the 9-11% range.

Titration

Four-weekly steps as with other weekly GLP-1 agonists.

Cycling

Chronic therapy, not cycled.

Work out your exact syringe units →

Pharmacology

Half-life
Long enough to support once-weekly dosing; precise human half-life not widely published.
Onset
Appetite effect within the first weeks; weight loss continued through 48 weeks in phase 3.
Routes
subcutaneous, oral
Molecule
Acylated long-acting GLP-1 receptor analogue

Handling

Diluent
Not applicable - supplied as a solution in China
Lyophilised
Not applicable.
Reconstituted
Refrigerated at 2-8 C.
Light sensitive
Yes — keep it out of the light

Side effects

  • very commonNausea— Standard GLP-1 class profile.
  • very commonDecreased appetite
  • commonDiarrhoea
  • commonVomiting

Do not use if

  • Personal or family history of medullary thyroid carcinoma or MEN2 - class effect.
  • History of pancreatitis.
  • Pregnancy.

Combining it

  • redundantsemaglutide — Same receptor.
  • cautioninsulin-analogues — Hypoglycaemia risk in combination.

What to monitor

  • · Weight.
  • · HbA1c.
  • · Heart rate.

Legal status

Approved in China for chronic weight management; investigational elsewhere.

References

  • SLIMMER phase 3 trial of ecnoglutide in Chinese adults with obesity (trial)
  • EECOH-2 phase 3 trial vs dulaglutide in type 2 diabetes, Lancet Diabetes Endocrinol 2025 (trial)

Mechanism in depth

Ecnoglutide's design premise is signalling bias. GLP-1 receptor activation recruits both Gs, which raises cAMP, and beta-arrestin, which drives receptor internalisation and desensitisation. Ecnoglutide was engineered to preferentially drive the cAMP arm while recruiting beta-arrestin poorly, on the theory that a receptor that does not internalise keeps signalling and that the desensitisation which limits chronic GLP-1 agonism can be designed around. This is the same general idea that shows up in tirzepatide's GLP-1 arm, taken further and made explicit. Whether it translates into a clinical advantage is a genuinely open question - the phase 3 obesity trial gave about 13% placebo-adjusted weight loss at 2.4 mg weekly, which is respectable and roughly semaglutide-like rather than clearly superior, and the EECOH-2 diabetes trial showed non-inferiority to dulaglutide rather than superiority to a modern comparator. The cleanest statement is that the biased-agonism hypothesis produced a drug that works about as well as the unbiased drugs, which is informative but not the breakthrough the mechanism promised. Approval is Chinese only, on Chinese-population trials with lower baseline BMI than Western obesity programmes.

What usually goes wrong

The main risk is believing the marketing. 'Biased agonism' is a real and interesting design principle, and the clinical result so far is a drug that performs roughly like semaglutide rather than better than it. Beyond that, the standard class problems apply - escalate too fast and you vomit, lose weight without training and protein and you lose muscle. The Chinese trial populations had lower baseline BMI than Western obesity trials, so percentage weight-loss figures do not transfer directly.

Titration ladder

  1. 1.2 mgEscalation — The phase 3 obesity programme studied 1.2, 1.8 and 2.4 mg weekly with stepwise escalation; the exact step durations were not verified here.
  2. 1.8 mgEscalation
  3. 2.4 mgMaintenance — The dose that produced roughly 13% placebo-adjusted weight loss at 48 weeks.

Bloodwork worth running

MarkerWhenWhy it matters
HbA1cBaseline and 3-monthly.Primary endpoint in the diabetes programme; EECOH-2 showed non-inferiority to dulaglutide.Act if: Below 6.0% on background insulin or sulfonylurea means cut that agent.
Weight and waistWeekly.The phase 3 obesity endpoint, around 13% placebo-adjusted at 48 weeks.Act if: None.
ALT and ASTBaseline and 6 months.As with other effective GLP-1 agonists, liver fat and transaminases fall with weight.Act if: A rise is unexpected and needs another explanation.
Creatinine and eGFRBaseline and after prolonged vomiting.Dehydration risk during gastrointestinal side effects, as with the whole class.Act if: A 30% rise means stop and rehydrate.

Pharmacokinetics

Crosses blood-brain barrier
partial
Accumulates
Yes — doses stack before steady state
Metabolism
Presumed proteolytic backbone cleavage plus beta-oxidation of the acyl chain, by analogy with other acylated GLP-1 analogues. Not confirmed.
Elimination
Presumed catabolic.

Receptor targets

  • GLP-1 receptor (GLP1R) — Not verified; the compound is characterised in the literature by its cAMP-versus-beta-arrestin bias rather than by raw affinity

    cAMP-biased agonism with reduced beta-arrestin recruitment, intended to reduce receptor internalisation and sustain signalling. Clinically produces the standard GLP-1 picture.

Trials

  • Phase 3 obesity trial (SLIMMER) Phase 3 · 48 weeks · 2025

    Placebo-adjusted weight reduction of approximately 13% at 2.4 mg weekly in Chinese adults with overweight or obesity.

  • EECOH-2 Phase 3 non-inferiority · 52 weeks · 2025

    Non-inferior HbA1c reduction versus dulaglutide in type 2 diabetes inadequately controlled on metformin.

  • EECOH-1 Phase 3 · 2026

    Ecnoglutide monotherapy versus placebo in type 2 diabetes.

What to expect, and when

Appetite effects within the first weeks; weight loss continued through 48 weeks in phase 3 without a clear plateau. Steady state timing is not published.

Stacking and comparisons

Redundant with every other GLP-1 agonist. In the diabetes trials it was used with metformin, which is the sensible background. There is no published combination work with amylin analogues or GIP agonists. As a Chinese-approved product it is not obtainable through Western pharmacy channels, and grey-market supply is unverifiable.

Against semaglutide: roughly comparable weight loss in its own phase 3, but never tested head-to-head against semaglutide, so 'comparable' is a cross-trial inference and cross-trial inference in obesity is unreliable. Against dulaglutide: non-inferior on HbA1c in EECOH-2, which is a low bar for a modern agent. Against mazdutide, the other Chinese-approved entrant: mazdutide adds a glucagon arm and has NEJM-published phase 3 data, which makes it the stronger of the two on evidence.

Rough cost

Approved in China only; Western pricing does not exist. Grey-market listings exist but identity cannot be verified.

Genuinely uncertain

  • No verifiable human pharmacokinetic parameters - tmax, volume of distribution, clearance, protein binding and bioavailability are all unresolved.
  • The exact sequence and acylation chemistry were not verified.
  • The 13% placebo-adjusted figure is from the phase 3 abstract-level result and was not verified against the full paper's primary analysis in this session.
  • Whether cAMP bias produces any clinical advantage over unbiased agonists remains unproven.
  • Titration step durations for the obesity programme were not verified.

Papers